/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $8.4 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Shares of this leading life sciences reagents and instruments company have considerably underperformed the broader market over the past year. TECH has declined 28.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.1%. In 2025, TECH stock is down 26%, compared to the SPX’s 9.7% rise on a YTD basis.
Narrowing the focus, TECH’s underperformance is also apparent compared to the iShares Biotechnology ETF’s (IBB). The exchange-traded fund has declined about 4.5% over the past year. Moreover, the ETF’s 4.7% returns on a YTD basis outshine the stock’s double-digit losses over the same time frame.
On Aug. 6, TECH shares closed down by 8.7% after reporting its Q4 results. Its adjusted EPS of $0.53 surpassed Wall Street expectations of $0.50. The company’s revenue was $317 million, exceeding Wall Street forecasts of $315.4 million.
For fiscal 2026, ending in June 2026, analysts expect TECH’s EPS to grow 2.9% to $1.76 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 17 analysts covering TECH stock, the consensus is a “Moderate Buy.” That’s based on 11 “Strong Buy” ratings, five “Holds,” and one “Strong Sell.”
This configuration is more bullish than a month ago, with 10 analysts suggesting a “Strong Buy.”
On Aug. 7, Conor McNamara from RBC Capital maintained a “Hold” rating on TECH with a price target of $61, implying a potential upside of 14.5% from current levels.
The mean price target of $64.57 represents a 21.2% premium to TECH’s current price levels. The Street-high price target of $75 suggests an ambitious upside potential of 40.7%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
